Mer­ck KGaA takes its I/O op­tion on F-star Ther­a­peu­tics; Nephron spends $215M, eye­ing spot in Covid-19 vac­cine chain

→Mer­ck KGaA has tak­en an ear­ly op­tion on an im­muno-on­col­o­gy pro­gram de­vel­oped at F-star Ther­a­peu­tics. This is their sec­ond op­tion in the col­lab­o­ra­tion. And they added a pair of pre­clin­i­cal dis­cov­ery pro­grams to the al­liance as well.

→ Any biotech go­ing pub­lic these days wouldn’t feel right if they didn’t up­size the of­fer­ing. And that’s just what Phase I biotech Pan­dion Ther­a­peu­tics did. The au­toim­mune com­pa­ny is now sell­ing 7 mil­lion shares, a 1.5 mil­lion share bump, for $16 to $18 a share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER